Expert: Professor Jorge Cortes Georgia Cancer Centre, Augusta (USA)

Program:
Overview of significant clinical aspects presented during the meeting, including:

• Olverembatinib as second-line therapy in patients with CP-CML  (00:42)
• Vamotinib versus imatinib in CML - first preliminary results (02:55)
• ELVN-001 in patients with previously treated CML - ENABLE phase 1 study (05:13)
• Asciminib studies (07:16)
  • Interim analysis of the phase 2 ASC2ESCALATE trial - Asciminib after 1 TKI (07:30)
  • 96-weeks results from the ASC4OPT study  - Asciminib once or twice daily (08:59)
  • Phase 3 ASC4START trial - Asciminib versus Nilotinib in newly diagnosed CP-CML patients (10:58)
• Dose reduction studies (12:11)
  • HALF Study - Treatment discontinuation after 2-step dose reduction (12:25)
  • RODEO Study - Patient-guided dose reduction of TKIs in CML (14:26)
• Next generation sequencing from dried blood spots in LMICs: "Spot on CML" results (15:31)
• Pediatric CML studies (16:53)
  • German CML-paed II Cohort - Second-line therapy in pediatric CML (16:56)
  • TFR in children with CML - Longer-term results from the Tata Memorial Hospital (18:07)

Please click here for the Biological Highlights.
If you have any questions or comments to the speaker, please email info@cml-foundation.org.